A Novel Immunofluorescence Assay for the Rapid Serological Detection of SARS-CoV-2 Infection.

ABSTRACT: As of April 2021, the COVID-19 pandemic has swept through 213 countries and infected more than 132 million individuals globally, posing an unprecedented threat to human health. There are currently no specific antiviral treatments for COVID-19 and vaccination programmes, whilst promising, remain in their infancy. A key to restricting the pandemic is the ability to minimize human-human transmission and to predict the infection status of the population in the face of emerging SARS-CoV-2 variants. Success in this area is dependent on the rapid detection of COVID-19 positive individuals with current/previous SARS-CoV-2 infection status. In this regard, the ability to detect antibodies directed against the SARS-CoV-Spike protein in patient sera represents a powerful biomarker for confirmation of

SUBMITTER: Nguyen D 

PROVIDER: S-EPMC8146438 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature